Legal Representation
Attorney
Cheryl Foytlin
USPTO Deadlines
Application History
22 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Jul 12, 2024 | MAB6 | E | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | Loading... |
| Jun 10, 2024 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED | Loading... |
| Nov 9, 2023 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Nov 7, 2023 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
| Nov 7, 2023 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
| Nov 7, 2023 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| May 9, 2023 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| May 5, 2023 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| May 5, 2023 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| May 5, 2023 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Nov 8, 2022 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Sep 13, 2022 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Sep 13, 2022 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Aug 24, 2022 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Aug 8, 2022 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Aug 8, 2022 | XAEC | I | EXAMINER'S AMENDMENT ENTERED | Loading... |
| Aug 8, 2022 | GNEA | F | EXAMINERS AMENDMENT E-MAILED | Loading... |
| Aug 8, 2022 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN | Loading... |
| Aug 8, 2022 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | Loading... |
| Aug 3, 2022 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Nov 24, 2021 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Nov 23, 2021 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Human pharmaceutical preparations for the prevention and treatment of viral diseases, auto-immune and inflammatory diseases, cardiovascular and pulmonary diseases, central nervous system diseases, peripheral neurological system diseases, pain, dermatologic diseases, gastro-intestinal diseases, infectious-related diseases, metabolic diseases, oncologic diseases, ophthalmic diseases, respiratory diseases, digital ulcers, and cerebrovascular diseases; vaccines; anxiolytics; pharmaceutical anti-allergic preparations and substances; anti-infectives
Classification
International Classes
005